FDA places partial halt on vantictumab trial

As expected, the FDA places a partial clinical hold on OncoMed's (OMED +8%) Phase 1 clinical trial for vantictumab. On Friday, the company announced a voluntary halt to patient enrollment and dosing in response to higher-than-expected adverse events. It is working with bone experts and investigators to assess the events and develop revised trial protocols.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs